898253-47-9

Upstream product

• 278597-30-1 [3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazol-4-yl]methanol 

Downstream Products

• 898253-48-0 4-(1-{4-[3-(2,6-dichloro-phenyl)-5-isopropyl-isoxazol-4-ylmethoxy]-3-methyl-phenyl}-1-ethyl-propyl)-2-methyl-phenol 
• 1103500-80-6 6-{4-[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-ylmethoxy]piperidin-1-yl}-1-methyl-1H-indole-3-carboxylic acid methyl ester 
• 1374961-96-2 4-{N-benzyl-2-chloro-4-{[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}benzamido}benzoic acid 
• 1374961-78-0 4-{[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}benzaldehyde 

Relevant academic research and scientific papers

Preparation and application of novel FXR small-molecule agonist

The invention discloses an FXR (farnesoid X receptor) micromolecule agonist and a preparation method thereof. The structure of the FXR micromolecule agonist is shown as a formula I. In the formula, the definition of each substituent group is described in the specification. The compound provided by the invention has the advantages of high FXR agonistic activity, simple synthesis, easily available raw materials and the like, and can be used for medicines for treating FXR related diseases.

COMPOUNDS AND METHODS FOR MODULATING FXR

Compounds of formula (I): formula (I) wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and diseases related to dyslipidemia.

COMPOUNDS AND METHODS FOR MODULATING FXR

Compounds of formula. wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.